Barely Significant
← all excerpts

Dasiglucagon for the Treatment of Congenital Hyperinsulinism: A Randomized Phase 3 Trial in Infants and Children.

J Clin Endocrinol Metab · 2024 · PMC10940263 · PMID 37930757

Europe PMCDOI
1
hedged sentence
0.1050
closest p · 2.1× alpha
0.1050
boldest claim

The sentences

showed a trendP = .105not close (p > 0.1)
A post hoc analysis showed a trend toward a treatment difference (−253 g/week [−563; 58] P = .105).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.